TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06707064

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SFEE Diet Management Intervention
Description: A structured diet management program designed to improve glycemic control, dietary adherence, and maternal outcomes. It includes:~Self-empowerment: Goal-setting, dietary planning, and evaluation. Family empowerment: Emotional support and supervision. Environmental empowerment: Peer group interaction and education via WeChat groups and in-person meetings.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dietary Advice
Description: Routine nursing care, including dietary education, exercise planning, and self-monitoring for gestational diabetes management.
Study: NCT06728228

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amnioinfusion
Description: A 20- or 22-gauge spinal needle (routinely used obstetrics and gynecology needle) will be used by an expert in fetal procedures with sterile technique to access the amniotic cavity under real-time ultrasound guidance to infuse isotonic fluid (Lactated Ringers with 1g/L of Oxacillin). This fluid will act as replacement amniotic fluid. Regular monitoring of fluid levels may suggest serial infusion, which will be completed as deemed necessary by the study doctor.
Study: NCT06731608

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OPTIONS
Description: OPTIONS is a multimodal intervention approach that includes providing clinical decision support (CDS) for healthcare providers, patients, and their caregivers focused on exercise, nutrition, and bone-enhancing medications using CDS in SNFs that use the same electronic health record system (PointClickCare).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: Enhanced usual care includes access to the STEADI (Stopping Elderly Accidents, Deaths, and Injuries) toolkit, a fall prevention program from the CDC.
Study: NCT06708013

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Transcranial Magnetic Stimulation Transcranial Magnetic Stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain. It\&#39;s primarily used to treat depression, especially in patients who haven\&#39;t responded well to traditional treatments like medications or psychotherapy. The most common target is the dorsolateral prefrontal cortex, a region often underactive in people with depression. The magnetic pulses stimulate or inhibit brain activity in the targeted area. This is believed to help reset or correct patterns of neural activity associated with depression and other psychiatric disorders. TMS represents an alternative for those struggling with depression, offering a non-invasive approach with relatively few side effects and significant potential benefits
Study: NCT06708871

Intervention type: PROCEDURE
Intervention: Thermal ablation
Description: Thermal ablation is a minimally invasive procedure used to treat primary hyperparathyroidism, a condition where one or more of the parathyroid glands produce excessive amounts of parathyroid hormone (PTH). The treatment involves using heat to destroy the overactive parathyroid tissue. This can be done through various methods such as radiofrequency ablation (RFA) and microwave ablation(MWA).

Intervention type: PROCEDURE
Intervention: Parathyroidectomy
Description: Parathyroidectomy is a surgical procedure to remove one or more of the parathyroid glands in cases of hyperparathyroidism.
Study: NCT06729645

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: External beam radiotherapy and endorectal brachytherapy
Study: NCT06729073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium gel
Description: topical administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac diethylamine 1.16% gel
Description: Topical administration
Study: NCT06736405

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pericapsular nerve group block
Description: Pericapsular nerve group block will be applied to patients in addition to standard treatment to prevent postoperative pain

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Pericapsular nerve group block
Description: Patients will be given standard treatment to prevent postoperative pain
Study: NCT06732856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolbetuximab
Description: 1. Neoadjuvant treatment~   : Zolbetuximab 800\*/600 mg/m2 Q3W on day (D) 1, Docetaxel 50 mg/m2 intravenously (IV) on D1, oxaliplatin 100 mg/m2 IV on D1, S-1 40 mg/m2 bid orally on D1-14, will be administered every three weeks for three cycles.~   (\*Loading dose of zolbetuximab (800 mg/m²) on C1D1, followed by subsequent doses of 600 mg/m² every 3 weeks)~2. Surgery~   : Total gastrectomy (TG) or distal gastrectomy (DG) accompanied with dissection of the D2 lymph node~3. Adjuvant treatment After 3-8 weeks from surgery, S-1 40/50/60 mg/m2 bid orally on D1-28 plus Zolbetuximab 600 mg/m2 on D1 and D22 will be administered every 6 weeks for 12 months as an adjuvant treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 1. Neoadjuvant treatment : Zolbetuximab 800\*/600 mg/m2 Q3W on day (D) 1, Docetaxel 50 mg/m2 intravenously (IV) on D1, oxaliplatin 100 mg/m2 IV on D1, S-1 40 mg/m2 bid orally on D1-14, will be administered every three weeks for three cycles. (\*Loading dose of zolbetuximab (800 mg/m²) on C1D1, followed by subsequent doses of 600 mg/m² every 3 weeks) 2. Surgery : Total gastrectomy (TG) or distal gastrectomy (DG) accompanied with dissection of the D2 lymph node 3. Adjuvant treatment After 3-8 weeks from surgery, S-1 40/50/60 mg/m2 bid orally on D1-28 plus Zolbetuximab 600 mg/m2 on D1 and D22 will be administered every 6 weeks for 12 months as an adjuvant treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 1. Neoadjuvant treatment : Zolbetuximab 800\*/600 mg/m2 Q3W on day (D) 1, Docetaxel 50 mg/m2 intravenously (IV) on D1, oxaliplatin 100 mg/m2 IV on D1, S-1 40 mg/m2 bid orally on D1-14, will be administered every three weeks for three cycles. (\*Loading dose of zolbetuximab (800 mg/m²) on C1D1, followed by subsequent doses of 600 mg/m² every 3 weeks) 2. Surgery : Total gastrectomy (TG) or distal gastrectomy (DG) accompanied with dissection of the D2 lymph node 3. Adjuvant treatment After 3-8 weeks from surgery, S-1 40/50/60 mg/m2 bid orally on D1-28 plus Zolbetuximab 600 mg/m2 on D1 and D22 will be administered every 6 weeks for 12 months as an adjuvant treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: 1. Neoadjuvant treatment : Zolbetuximab 800\*/600 mg/m2 Q3W on day (D) 1, Docetaxel 50 mg/m2 intravenously (IV) on D1, oxaliplatin 100 mg/m2 IV on D1, S-1 40 mg/m2 bid orally on D1-14, will be administered every three weeks for three cycles. (\*Loading dose of zolbetuximab (800 mg/m²) on C1D1, followed by subsequent doses of 600 mg/m² every 3 weeks) 2. Surgery : Total gastrectomy (TG) or distal gastrectomy (DG) accompanied with dissection of the D2 lymph node 3. Adjuvant treatment After 3-8 weeks from surgery, S-1 40/50/60 mg/m2 bid orally on D1-28 plus Zolbetuximab 600 mg/m2 on D1 and D22 will be administered every 6 weeks for 12 months as an adjuvant treatment.
Study: NCT06741670

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Description: The routine practice of the Breastfeeding Group is to place the infants in their mother's arms and start breastfeeding 1 minute before the procedure. Then, the nurse will take the heel blood.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration
Description: The vibration device was placed on the infant's left extremity in the mid/lateral region just below the knee where the sural nerve passes. The device was secured to the extremity with a gauze bandage. The infants in the Vibration Group will be placed in their mother's arms and vibration will be applied 30 seconds before the routine application, and vibration will be applied during the 10-second waiting phase while the nurse performs the heel prick blood collection procedure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breastfeeding+Vibration
Description: The vibration device was placed on the infant's left extremity in the mid/lateral region just below the knee where the sural nerve passes. The device was secured to the extremity with a gauze bandage.~The routine practice for the Breastfeeding+Vibration Group babies will be started by holding them in their mother's arms and breastfeeding will be started 1 minute before the application. At the same time, vibration will be applied 30 seconds before the application and vibration will be applied in a 10-second waiting phase while the nurse performs the heel prick procedure.
Study: NCT06741384

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diaphragmatic breathing exercises
Description: Participants will be directed to position their hands on the rectus abdominis muscle located under the anterior chest wall while resting in a hook position. They will be instructed to inhale slowly and deeply via the nostrils, expanding their abdomen without raising their upper chest, and resting their shoulders. Following the cessation of respiration, the woman will slowly exhale by pursing her lips. A respiratory cycle will consist of a three-second inhalation, a three-second pause, and a six-second exhalation. The diaphragmatic training regimen will consist of doing 3-5 sets of 5-10 deep breaths, with 2-minute intervals of rest in between sets.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic training
Description: The women will participate in aerobic training on cycle ergometer. Each session will consist of 30-45 minutes of cycling at a moderate intensity, accompanied by a workout heart rate ranging from 65% to 75% of the maximal heart rate and ranging between 12 and 14 on the Borg rating of perceived exertion 20-point scale. After ten minutes of warm-up, every session will end with a brief 3-minute period of cool-down.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic training
Description: The women will participate in aerobic training on cycle ergometer. Each session will consist of 30-45 minutes of cycling at a moderate intensity, accompanied by a workout heart rate ranging from 65% to 75% of the maximal heart rate and ranging between 12 and 14 on the Borg rating of perceived exertion 20-point scale. After ten minutes of warm-up, every session will end with a brief 3-minute period of cool-down.
Study: NCT06744270

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: i-PRF group
Description: In the i-PRF group, 10 ml of venous blood taken from the patient immediately after the SDG operation will be transferred to a tube that does not contain any anticoagulant. The collected venous blood will be centrifuged for 3 minutes at 2300 rpm in a centrifuge device and two layers will be obtained: the lower layer is red blood cells and the upper layer is i-PRF. 20-25 minutes will be waited for polymerization. After polymerization, the polymerized i-PRF will be applied to the wound surface in the donor area. Following the operation, patients will be called for check-ups on the 3rd, 5th, 7th, 14th, 21st and 30th days and their photographs will be taken and the following parameters will be evaluated.~* Pain assessment and analgesic intake~* H2O2 Foaming Test (to assess epithelialization)~* Wound healing will be assessed using the Image program from patient photographs~* Edema and erythema scores will be assessed visually.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low-dose laser group
Description: In the laser group, low-dose laser will be applied to the palatal donor area immediately after SDG surgery, on the 3rd, 5th, 7th and 14th days. A GaAlAs diode laser (CHEESETM, GIGAA Laser, Wuhan Gigaa Optronics Technology Co., Ltd., China) with a wavelength of 810 nm and a low-dose diode laser application tip with a fiber diameter of 950 µm will be used. A low-dose diode laser will be applied to the surgical operation area in accordance with the manufacturer's instructions, with a non-contact regional 0.3 W power and an intensity of 4 J/cm2 in continuous mode for 1 min. Following the operation, patients will be called for check-ups on the 3rd, 5th, 7th, 14th, 21st and 30th days, and their photographs will be taken and the following parameters will be evaluated. • Pain assessment and analgesic intake~* H2O2 Foaming Test (to assess epithelialization)~* Wound healing will be assessed using Image program from patient photographs~* Edema and erythema scores will be assessed visually.
Study: NCT06745700

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioural Activation
Description: Behavioral: Brief Behavioral Activation.~A five-session telephone-based brief behavioral activation treatment.~Session 1: Psychoeducation about depression; treatment rationale for Behavioral Activation (BA); rationale and instructions for activity log.~Session 2: Discussion of life goals and values; planning of activities aligned with life goals and values for coming week.~Session 3-4: Troubleshooting any problems carrying out activities; planning activities aligned with life goals and values for coming week.~Session 5: Troubleshooting any problems carrying out activities; reviewing treatment; stressing the importance of continuing to engage in activities aligned. with life goals and values; creating a a maintenance plan.~Other group: care as usual.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care as usual
Description: Care as usual provided by Region Västamanland,

Intervention type: OTHER
Group type: OTHER
Intervention: Care as usual
Description: Care as usual provided by Region Västamanland,
Study: NCT06744556

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: daunorubicin
Description: Used in combination with cytarabine and venetoclax for induction therapy in DAV.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venetoclax
Description: Used in combination with cytarabine and daunorubicin for induction therapy in DAV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Used in combination with cytarabine and daunorubicin for induction therapy in DAV.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cytarabine
Description: Used in combination with venetoclax and daunorubicin for induction therapy in DAV or used by intermediate does for consolidation therapy.
Study: NCT05062200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered as an oral tablet.
Study: NCT06744556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Used in combination with venetoclax and daunorubicin for induction therapy in DAV or used by intermediate does for consolidation therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azacitidine
Description: Used in combination with venetoclax for maintenance therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Used in combination with venetoclax for maintenance therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Homoharringtonine
Description: Used in combination with cytarabine and venetoclax for induction therapy in HAV.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Idarubicin
Description: Used in combination with cytarabine and venetoclax for induction therapy in IAV.
Study: NCT06740474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-6250
Description: Single dose (SAD) or once or twice daily dosing over 10 days (MAD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-6250
Description: Single dose (SAD) or once or twice daily dosing over 10 days (MAD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-6250
Description: Single dose (SAD) or once or twice daily dosing over 10 days (MAD)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose (SAD) or once or twice daily dosing over 10 days (MAD)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose (SAD) or once or twice daily dosing over 10 days (MAD)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose (SAD) or once or twice daily dosing over 10 days (MAD)
Study: NCT06738316

Intervention type: BEHAVIORAL
Intervention: Simulation
Description: Simulation of a patient safety incident in practice. The simulation closely replicates the workplace experience.
Study: NCT06738342

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHX 0.09% + Citrox + HA
Description: The patient will use the assigned mouthwash starting 24 hours after the surgical procedures and continuing twice a day for 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHX 0.12%
Description: The patient will use the assigned mouthwash starting 24 hours after the surgical procedures and continuing twice a day for 14 days.
Study: NCT06739083

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-mentoring program
Description: The e-mentoring program is planned to last four weeks to facilitate the adaptation process of newly recruited nurses in intensive care units via the e-mentoring website.
Study: NCT06736522

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Leadership, Engagement, and youth Activism Program with Mindfulness
Description: The Leadership, Engagement, and youth Activism Program with Mindfulness intervention (LEAP) was designed and co-created with youth to improve youth wellbeing by enhancing civic engagement and leadership opportunities and by developing mindfulness in day-to-day life. LEAP seeks to foster these improvements in youth of color and to increase youth mental, emotional, and behavioral health. Youth voice is incorporated into the intervention, with facilitators leading the first 7 sessions, and youth leading the remainder.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EnvisionIT
Description: Participants in this arm will receive 14 sessions of EnvisionIT training, focused on preparing students with essential transition skills and digital literacy through competency in information technology, financial literacy, English language arts skills, and college and career readiness. All sessions will be delivered by facilitators trained in EnvisionIT.
Study: NCT06745362

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-monitoring of breath acetone
Description: Participants perform self-monitoring of braeth acetone in order to get information about their ketosis state.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lifestyle-intervention via LIM-App
Description: Participants are offered a lifestyle intervention via LIM-App.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lifestyle-intervention via LIM-App
Description: Participants are offered a lifestyle intervention via LIM-App.
Study: NCT06734104

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interactive Video Education
Description: After participants are informed about the study, eligible individuals (based on inclusion and exclusion criteria) will be identified. From the students deemed eligible for the study group, 60 students will be selected using a simple random sampling method by an independent statistician. Informed consent will be obtained from students who agree to participate in the study. Initially, a pre-test will be administered to the 60 selected students. Following the pre-test, the students will be randomly assigned to the experimental and active control groups using a simple randomization method. The researcher will provide the interactive video to the students in the experimental group. After one week of interactive video training for the experimental group, a post-test will be administered to all students.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-Interactive Video Education
Description: After participants are informed about the study, eligible individuals (based on inclusion and exclusion criteria) will be identified. From the students deemed eligible for the study group, 60 students will be selected using a simple random sampling method by an independent statistician. Informed consent will be obtained from the students who agree to participate in the study. Initially, a pre-test will be administered to the 60 selected students. After the pre-test, the 60 students will be randomly assigned to the experimental and active control groups using a simple randomization method. The researcher will provide the non-interactive video to the students in the active control group. After one week of watching the non-interactive video, a post-test will be administered to all students.
Study: NCT06735911

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spa therapy
Description: Thermal treatments among the following: Filiform shower, simple bath, aerated bath, general shower, compresses, nebulization inhalation, multiple local mud applications, and drinking cure.
Study: NCT06744621

Intervention type: OTHER
Intervention: Fingerstick
Description: fingersticks during their labor process
Study: NCT06743802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10
Description: Coenzyme Q10 was administered from admission to one month after discharge at a dose of 200 mg per day (200 mg/qd).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo was administered from hospital admission until one month after discharge.
Study: NCT06744608

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Structured Myofascial Release
Description: haftada 2 seans 8 hafta boyunca toplam 16 seans uygulama yapıldı

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tens (transcutaneous electrical nerve stimulation)
Description: A total of 16 sessions of application were applied to the groups, 2 sessions per week for 8 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: lifestyle changes
Description: A presentation including lifestyle changes was prepared and training was provided.
Study: NCT06744439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1015
Description: One tablet administered alone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BR1015-2
Description: One tablet administered alone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BR1015-3
Description: One tablet administered alone
Study: NCT06745596

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cataract surgery 1
Description: Cataract with limited anterior pars plana vitrectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cataract surgery 2
Description: cataract without limited anterior pars plana vitrectomy
Study: NCT06744699

Intervention type: OTHER
Intervention: Infants fed goat milk-based infant formula
Description: Type of infant feeding during the age of 0-12 months